Skip links and navigation

For consumer representatives

Consumer Opportunities

Expression of Interest – Advancing Kidney Care 2026 Collaborative Committee

Closing date: close of business Wednesday, 26 September 2018


Department of Health, System Planning Branch

The Department of Health’s System Planning Branch is seeking two consumer representatives to join the Advancing Kidney Care 2026 Collaborative (the Collaborative). The Collaborative would greatly benefit through the participation of an Aboriginal and Torres Strait Islander consumer representative.

About System Planning Branch

System Planning Branch is responsible for leading health service planning activities of statewide significance with a medium to long term horizon. This role entails:

  1. Identifying the comparative health service needs of localities, populations and patient cohorts (both current and over the anticipated medium to long term future) to inform the statewide allocation of resources to achieve service access equity
  2. Facilitating integration of planning at the system level to align service enablers with future need e.g. workforce, infrastructure, funding
  3. Facilitating vertical integration of planning for health services between the Department of Health (DOH) and Hospital and Health Services (HHS) through identification of high level service directions and service outcomes, to act as a point of alignment for health service planning and investment by the DOH, HHS and service partners from the private and not-for-profit sectors
  4. Supporting other departmental and HHS level planning processes through provision of technical expertise in health service planning content and process, including technical analysis on projected service need.


The Advanced Kidney Care 2026 Collaborative Committee will be responsible for implementing the strategic actions arising from recently completed statewide planning for renal health and renal health services. Members are being appointed to 30 June 2019.

The specific aims of the Collaborative include (to be ratified by members)

  1. Implement the strategic directions and priority actions in Advancing Kidney Care 2026.
  2. Develop a workplan and review progress against the workplan at each meeting.
  3. Advocate for timely access to quality renal care with the Minister for Health and Ambulance and Boards and Executive of HHS, aligned with consumer views of what matters.
  4. Ensure that initiatives and decisions to be implemented within HHSs are sensitive to the local context based on recommendations from sub-Collaboratives and/or structured engagement that includes representation from the executive and clinical leadership (multidisciplinary) within each HHS.
  5. Champion initiatives that promote the effective and optimal use of available resources.


Read more  

Expression of Interest – Fourth Statutory Review of the Dental Benefits Act 2008 Review Committee

Closing date: close of business midnight AEST on Sunday 23 September 2018


Consumers Health Forum of Australia

The Dental Benefits Act 2008 (the Act) is the mechanism under which the Australian Government pays benefits for dental services to eligible dental patients. The Act provides a legal framework for the Child Dental Benefit Schedule. Section 68 stipulates that the Minister for Health must cause an independent review of the operation of the Act to be undertaken as soon as possible after the first anniversary of the commencement of the Act; and further independent reviews as soon as practicable after the Act’s third anniversary and at three yearly intervals thereafter. Section 68 of the Act requires the Consumers Health Forum of Australia (CHF) to nominate a consumer representative to participate In the Review Committee.

The Review Committee comprises of the following persons:

  • person occupying the position of Commonwealth Chief Medical Officer;
  • a person nominated by the Australian Dental Association;
  • a person nominated by the Consumers’ Health Forum of Australia; and
  • two other persons nominated by the Minister, at least one of whom must have qualifications in medicine or dentistry.

The Review Committee will undertake the fourth independent review of the Dental Benefits Act 2008 (the Act) and will assess the practical operation of the Act in regard to access and delivery of services, including an assessment of:

  • eligibility notification and confirmation processes;
  • claiming processes; and
  • the Informed Financial Consent regime.

The Review Committee may also consider opportunities to improve the operation and administration of the Child Dental Benefits Schedule to allow for the most efficient, effective and sustainable delivery of dental benefits and services.

Role of the Consumer

The work of the Review Committee will consist of meetings in Canberra plus out of session work as necessary from October 2018, with the report provided to the Minister of Health In early 2019. Meeting dates have yet to be confirmed. Please note that travel costs and sitting fees will be covered by the Department of Health for this work.

How to apply

CHF invites expressions of interest from consumer representatives by midnight AEST on Sunday 23 September 2018. The details of two consumer representatives will be forwarded to the Minister of Health for possible appointment. Interested consumer representatives will need to:

  • Complete a CHF nomination form available online at
  • Attach a letter of endorsement from a supporting health consumer organisation and/or provide sound demonstration of your links with a consumer base. This information ensures that consumer representatives are accountable to consumers. Please note that the health consumer group need not be a CHF member. This process ensures consumer representatives are placed with the confidence of consumers and have in place a consultative base enabling reps to draw from and report to consumers.
  • Attach a short CV in pdf format to be forwarded to the Department of Health

Please contact Ghislaine Martin on 02 6273 5444 or via email at should you have any queries.

Expressions of Interest – Department of Health – Prostheses Clinical Advisory Groups

The Department of Health is seeking consumer representation for eight Prostheses Clinical Advisory Groups.


The Prostheses List Advisory Committee (PLAC) advises the Minister on the suitability to list on the Prostheses List under the Private Health Insurance Act 2007. The Prostheses List Clinical Advisory Groups (CAGs) are expert sub-committees of the Prostheses List Advisory Committee (PLAC) providing advice on issues relating to the clinical effectiveness of prostheses, including effectiveness compared to other devices. The PLAC makes recommendations to the Minister on which products are listed on the Prostheses List. Listing on the Prostheses List affects whether or not a prostheses benefit is available to consumers from a private health insurer.


Consumer Opportunity

Nominations/renominations are now due for the following Clinical Advisory Groups:

  • Prostheses Clinical Advisory Group – Specialist Orthopaedic
  • Prostheses Clinical Advisory Group – Cardiac
  • Prostheses Clinical Advisory Group – Cardiothoracic
  • Prostheses Clinical Advisory Group – Ophthalmic
  • Prostheses Clinical Advisory Group – Orthopaedic (Hips)
  • Prostheses Clinical Advisory Group – Orthopaedic (Knees – KPCAG)
  • Prostheses Clinical Advisory Group – Spinal
  • Prostheses Clinical Advisory Group – Vascular Stents and Grafts

The CAGs refer applications to the Medical Services Advisory Committee (MSAC) where the:

  • New medical device employs a medical service that is not currently covered in the Medicare Benefits Schedule (MBS), or
  • New medical device might be used in a medical service that is currently described in the MBS, but potentially extends the range of indications/patients beyond the original intent of the MBS item/s.

The CAGs also advise the PLAC on:

  • The evidence and information they require to assess applications to list medical devices on the Prostheses List.
  • Any concerns in relation to safety and/or performance of medical devices, for referral to the Therapeutic Goods Administration.
  • Reviewing the listing of medical devices in view of issues relating to comparative health outcomes.
  • On any other matter, as required.
Read more